Skip to Main Content

Skip Nav Destination

.Getting the Most from Minimal Residual Disease| November 5, 2020

Advances in Mass Spectrometry for Myeloma Minimal Residual Disease

Katie Thoren

Katie Thoren

1Memorial Sloan Kettering Cancer Center, New York, NY

Search for other works by this author on:

PubMed

Google Scholar

Blood (2020) 136 (Supplement 1): SCI1.

https://doi.org/10.1182/blood-2020-133038

Sign in via your Institution

Supplemental data